Published July 21, 2026
Drug Pipeline Insights: Generic Pharmaceuticals (2026 Q2)
Our 2026 Q2 Drug Pipeline Insights: Generic Pharmaceuticals explores the latest generic approvals and pipeline developments, including the arrival of generic semaglutide and major market trends that …
Read more about Drug Pipeline Insights: Generic Pharmaceuticals (2026 Q2)Published July 21, 2026
Drug Pipeline Insights: Biosimilars (2026 Q2)
Our 2026 Q2 Drug Pipeline Insights: Biosimilars Insights examines the latest biosimilar approvals, evolving market dynamics and important regulatory changes that could accelerate future biosimilar co…
Read more about Drug Pipeline Insights: Biosimilars (2026 Q2)Published July 21, 2026
Drug Pipeline Insights: New Drugs (2026 Q2)
Our 2026 Q2 Drug Pipeline Insights: New Drugs highlights the latest wave of innovative therapies entering the Canadian market from breakthrough treatments for rare diseases and Alzheimer's disease to…
Read more about Drug Pipeline Insights: New Drugs (2026 Q2)Published July 20, 2026
From the Desk of the CEO - 2026 Q2 Update
Neighbourhood Pharmacies releases its Q2 2026 From the Desk of the CEO letter and advocacy updates.
Read more about From the Desk of the CEO - 2026 Q2 UpdatePublished July 2, 2026
The Economic Footprint of Canada's Pharmacy Sector
Commissioned by the Neighbourhood Pharmacy Association of Canada and independently prepared by Signal49 Research, The Economic Footprint of Canada's Pharmacy Sector: Fuelling Health and Local Economi…
Read more about The Economic Footprint of Canada's Pharmacy SectorPublished April 21, 2026
Drug Pipeline Spotlight: Semaglutide
Our Drug Pipeline Spotlight on Semaglutide explores the explosive growth of GLP-1 therapies like Ozempic, Wegovy, and Rybelsus, the anticipated entry of generics in 2026, and what it all means for ph…
Read more about Drug Pipeline Spotlight: Semaglutide